Armis Helps Italian Grocery Retailer Multicedi Strengthen Cyber Resilience
20.1.2026 13:00:00 CET | Business Wire | Press Release
Armis, the cyber exposure management & security company, today announced that Multicedi, one of the leading grocery retail groups in Central and Southern Italy, is using Armis Centrix™, Armis’ Cyber Exposure Management Platform, to strengthen its cybersecurity posture.
“Before introducing Armis, critical issues were addressed only when malfunctions or abnormal events had already occurred,” said Livio De Prisco, Director of Information Systems at Multicedi. “With Armis Centrix™, the approach has completely changed: rather than responding reactively, the company now has a real-time view of its entire device fleet and can manage it proactively. We can detect devices that have been added to the network, prioritize risks based on their criticality, and define action plans and budgets consistent with our operational and regulatory requirements.”
In recent years, Multicedi launched a comprehensive digital transformation program to modernize its application landscape and infrastructure backbone. This process transformed the accounting, logistics, and commercial management systems, requiring a thorough overhaul of the company’s IT architecture with a gradual shift of workloads to cloud environments. As Multicedi manages a complex network of over 2,500 physical and virtual assets across central environments, secondary sites, and remote warehouses, the security team recognized cybersecurity as essential to supporting this transformation.
Within the first month of deploying Armis Centrix™ across Multicedi’s main network hub, the platform identified that 10–15% of devices active on the network were previously unregistered or unknown. The ability to detect unauthorized or unsupervised devices on the network, which is common in complex organizations such as Multicedi that have multiple logistics sites and autonomous operating units, enabled IT teams to take timely action, preventing unknown vulnerabilities from compromising overall security. Armis also enabled the IT team to identify the precise physical location of connected assets, mapping switches, and network ports, allowing faster response in the event of anomalies, disconnections, or replacements.
“Cybersecurity is essential to business continuity, especially in critical infrastructure sectors such as retail, as we’ve seen global cyberattacks earlier this year leave grocery store shelves empty,” said Nicola Altavilla, Regional Director, Mediterranean at Armis. “Staying a step ahead of attackers is more important than ever, given the advancements of AI-powered bad actors looking to cause disruption. Armis is proud to support global retailers like Multicedi to enhance their cybersecurity and to take a more proactive approach to protecting their environment from cybercriminals.”
Following the success of the initial deployment, Multicedi plans to extend Armis Centrix™ to its entire network of over 600 direct and affiliated stores. The goal is to establish shared cybersecurity standards across more than 250 partner organizations, adapting the platform to suit different operating contexts in terms of the number of devices, type of environment, and investment capacity. Armis Centrix™ will serve as a foundational pillar supporting Multicedi’s long-term digital evolution, enabling secure growth, improved governance, compliance with national and EU directives, and a strengthened security culture across the entire organization.
Read the full case study with additional details on the collaboration between Multicedi and Armis here.
Find additional details on how Armis is supporting global customers across industries here.
About Armis
Armis, the cyber exposure management & security company, protects the entire attack surface and manages an organization’s cyber risk exposure in real time. In a rapidly evolving, perimeter-less world, Armis ensures that organizations continuously see, protect, and manage all critical assets—from the ground to the cloud. Armis secures Fortune 100, 200, and 500 companies as well as national governments, state and local entities, and critical infrastructure operators to help keep economies and societies safe and secure 24/7. Armis is a privately held company headquartered in California.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260120440952/en/
Contacts
Media:
Rebecca Cradick
Vice President, Global Communications
Armis
pr@armis.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering11.3.2026 07:00:00 CET | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 1.6 million shares at a price of CHF 143.75 per share for a total consideration of CHF 232 million in the context of the accelerated bookbuild offering (“ABO”) of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (Private Equities Department) and Auba Investment Pte. Ltd. (all together the “Selling Shareholders”) launched yesterday evening. The repurchase was made at the same price per share determined by the bookbuilding offering. As a result of yesterday evening’s ABO, the Selling Shareholders have fully divested their remaining stake in Galderma. The repurchase, which is expected to settle on March 13 is being financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to deliver on its strategic and financing priorities. The shares will be held in treasury for future use in connection with Galderma's employe
Thales Launches SkyDefender: The Integral Air and Missile Defence Dome With Artificial Intelligence11.3.2026 07:00:00 CET | Press Release
As air and missile threats are evolving faster than ever, from slow-moving drones to hypersonic missiles, attacks are becoming increasingly complex, saturating and unpredictable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310398606/en/ SkyDefender © Thales Thales SkyDefender provides full protection against all types of air threats, from a few kilometres to several thousands of kilometres: Short-range: for protection of forces, vital assets and sensitive sites: ForceShield creates a real protection bubble against lower layer and surface threats at very short- and short-range, such as drones. Medium-range: for protection at theatre-level defence: SAMP-T NG by eurosam1 with up to 150 km engagement range, including Thales’ powerful Ground Fire radar with 350 km range and 360°/90° coverage against medium-range defence. Long-range: for protection against long-range threats with early-warning capabilities: a unique capacity
Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan11.3.2026 07:00:00 CET | Press Release
Curatis Holding AG (SIX: CURN) and Neupharma Co., Ltd. (“Neupharma”), a Japanese pharmaceutical company specializing in oncology, immunology, pulmonology and cardiology disorders, today announce an exclusive license and development agreement for corticorelin (C-PTBE-01) in Japan. Under the terms of the agreement, Neupharma will receive exclusive rights to develop and commercialize corticorelin for the treatment of peritumoral brain edema (PTBE) in Japan. PTBE is a tumor-associated condition for which no approved targeted therapies currently exist. Neupharma will finance and conduct a pivotal clinical trial in Japan to support filing for approval in Japan. Curatis will receive upfront and milestone payments for the achievement of regulatory and commercial targets totaling up to CHF 83.5 million, as well as royalties on future sales in Japan of up to 20%. The agreement stipulates that corticorelin is planned to be introduced in Japan initially for children and adolescents. A meeting with
FERM FOOD Acquires Orkla’s Former Site and Scales Up: Up to 20,000 Tonnes of Fermented Ingredients Per Year11.3.2026 07:00:00 CET | Press Release
Danish ingredient producer FERM FOOD is acquiring Orkla’s former manufacturing site in Skovlund, Denmark, effective 1 April 2026. The acquisition provides new production facilities to expand the output of fermented plant-based ingredients for the food industry — driven by export demand that has emerged faster than expected. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310904877/en/ Jens Legarth (CEO), Rikke Matthiesen (CSO), and Torbjørn Tyndkjær-Thomsen (Food & Process Developer) at FERM FOOD’s new production facilities. “We have outgrown our current facilities. With the Skovlund site, we can supply many more food manufacturers in Denmark and abroad. Global interest has developed faster than we expected — and that is why we are scaling up now,” says Jens Legarth, CEO of FERM FOOD. Once fully ramped up, the new fermentation facility is expected to reach an annual capacity of up to 20,000 tonnes, depending on product mix
Galderma Completes Successful Placement of EUR 500 Million Eurobond11.3.2026 06:55:00 CET | Press Release
Galderma Group AG (SWX:GALD): NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the successful placement of a single-tranche EUR 500 million Eurobond. The bond has a 5-year maturity and carries a fixed-rate annual coupon of 3.375%. The Eurobond was placed on March 10, 2026, with settlement expected on March 17, 2026, and will be listed on the SIX Swiss Exchange. Citigroup, ING, J.P. Morgan and RBC Capital Markets jointly led the transaction. Net proceeds from the transaction will be used to fully repay Galderma’s existing bank term loan issued in connection with the company’s initial public offering in March 2024. The transaction represents the final step in Galderma’s refinancing process, having obtained two investment grade credit ratings. Galderma is currently rated ‘BBB’ (stable outlook) by Fitc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom